Dermcidin (
DCD) is a human gene mapped to chromosome 12q13 region, which is co-amplified with multiple oncogenes with a well-established role in the growth, survival and progression of breast
cancers. Here, we present a summary of
a DNA microarray-based study that identified the genes that are up- and down-regulated in a human MDA-361 pLKO control clone and three clones expressing
short hairpin RNA against three different regions of
DCD mRNA. A list of 235 genes was differentially expressed among independent clones (> 3-fold change and p < 0.005). The gene expression of 208 was reduced and of 27 was increased in the three
DCD-RNAi clones compared to pLKO control clone. The expression of 77 genes (37%) encoding for
enzymes involved in
amino acid metabolism,
glucose metabolism and
oxidoreductase activity and several genes required for cell survival and DNA repair were decreased. The expression of EGFR/ErbB-1 gene, an important predictor of outcome in
breast cancer, was reduced together with the genes for
betacellulin and
amphiregulin, two known
ligands of EGFR/
ErbB receptors. Many of the 27 genes up-regulated by
DCD-RNAi expression have not yet been fully characterized; among those with known function, we identified the
calcium-calmodulin-dependent protein kinase-II delta and
calcineurin A alpha. We compared 132 up-regulated and 12 down-regulated genes in our dataset with those genes up- and down-regulated by inhibitors targeting various signaling pathway components. The analysis showed that the genes in the
DCD pathway are aligned with those functionally influenced by the drugs
sirolimus,
LY-294002 and
wortmannin. Therefore,
DCD may exert its function by activating the PI3K/AKT/mTOR signaling pathway. Together, these bioinformatic approaches suggest the involvement of
DCD in the regulation of genes for
breast cancer cell metabolism, proliferation and survival.